NUCALA (GlaxoSmithKline Australia Pty Ltd)
Product name
NUCALA
Date registered
Evaluation commenced
Decision date
Approval time
189 (255 working days)
Active ingredients
mepolizumab
Registration type
EOI
Indication
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
NUCALA (solution for injection) is now also indicated as add-on treatment in adult patients (18 years and above) with severe chronic rhinosinusitis with nasal polyps (CRSwNP) with an inadequate response to intranasal corticosteroids (see section 5.1 Pharmacodynamic properties, clinical trials).